Viking Therapeutics Inc
VKTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.75B
Close$
$1.47
95.7% downside
Current Fair Value
95.7% downsideOvervalued by 95.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.75 Billion |
|---|---|
| Enterprise Value | $3.63 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.19 |
| Beta | 0.69 |
| Outstanding Shares | 115,917,000 |
Return
| Return on Equity | -130.98% |
|---|---|
| Return on Assets | -102.47% |
| Return on Invested Capital | -134.74% |
Valuation & Multiples
| P/E Ratio | -6.9 |
|---|---|
| PEG | -7.24 |
| Price to Sales | - |
| Price to Book Ratio | 11.33 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -6.54 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 29, 2026
EPS Estimate
$-1.23
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
October 28, 2026
EPS Estimate
$-1.07
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3452▲ 2.67% |
|---|---|
| Total Calls | 7,810,569▲ 25.80% |
| Total Puts | 2,696,194▲ 36.34% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 70.39%▲ 6.95% |
|---|---|
| Total Invested | $3.11B▲ 27.83% |
| Investors Holding | 469▲ 27.00% |
ESG Score
No data
About Viking Therapeutics Inc
CEO: Brian Lian